What question did this study set out to answer?

To evaluate the efficacy and safety of a taxane/carboplatin/trastuzumab/pertuzumab regimen in HER2-positive breast cancer patients.

Neoadjuvant Taxane/Carboplatin/Trastuzumab/Pertuzumab in Patients with HER2-Positive Early or Locally-Advanced Breast Cancer: A Retrospective, Single-Center, Observational Study

View Full Paper

Ask AI

Bookmark

Authors

Retrospective study shows high pathologic complete response rates in HER2-positive breast cancer, indicating effective treatment options.

To evaluate the efficacy and safety of a taxane/carboplatin/trastuzumab/pertuzumab regimen in HER2-positive breast cancer patients.
Retrospective observational study conducted at a single center
Patients with early-stage or locally advanced HER2-positive breast cancer treated with a specified regimen from April 2018 to September 2024
Pathologic complete response (pCR) assessed post-surgery, and adverse events recorded based on patient reports
Overall pCR rate was 56.1% (23 out of 41 patients)
Higher pCR rates were observed in hormone receptor-negative (63.6%) and node-negative tumors (100%)
Docetaxel-based regimens had higher pCR rates compared to nondocetaxel regimens (74.1% vs. 21.4%), with statistical significance
61% of patients were able to undergo breast-conserving surgery, with 84% achieving pCR among them
Weekly paclitaxel/carboplatin showed improved tolerability compared to docetaxel-based therapy

Kukkar et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark